WPP Group PLC
17 November 1999
WPP GROUP ('WPP')
OGILVY GROUP UK AND COMMONHEALTH ACQUIRE UK HEALTHCARE
AGENCY, MATTHEW POPPY ADVERTISING LIMITED
WPP announces that its wholly-owned operating companies,
Ogilvy Group UK, the advertising agency group and
CommonHealth, the global healthcare communications company,
have acquired Matthew Poppy Advertising Ltd, the UK's
largest independent healthcare advertising agency.
The London-based agency provides total healthcare
communications to clients such as Bristol-Myers Squibb,
Glaxo Wellcome, Novo Nordisk and Pharmacia & Upjohn. The
company employs 27 people and reported revenues of £1.3
million to 31 July 1999 and net assets of £49,000 at that
date.
The acquisition will provide Matthew Poppy's clients with
full access to the wider resources of the OgilvyHealthcare
network across Europe and to CommonHealth's resources
worldwide.
This acquisition continues WPP's strategy of developing its
business in the faster growing segments of the communications
services industry. This is the latest in a series of joint
ventures by CommonHealth with other WPP companies. Earlier
this month it announced the formation of healthcare/brand/promotion
group EinsonHealth, with Einson Freeman, WPP's US promotional
marketing specialists.
Contact:
Feona McEwan, WPP London 44-20 7408 2204
www.wpp.com
www.ogilvy.com
www.commonhealth.com
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.